475 related articles for article (PubMed ID: 33574756)
1. Potential of Immune-Related Therapy in COVID-19.
Yuan C; Li R; Liu G; Pan Y
Front Pharmacol; 2020; 11():609212. PubMed ID: 33574756
[TBL] [Abstract][Full Text] [Related]
2. Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update.
Kumari P; Rawat K; Saha L
Curr Pharmacol Rep; 2020; 6(5):228-240. PubMed ID: 32837854
[TBL] [Abstract][Full Text] [Related]
3. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
4. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
5. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.
Bchetnia M; Girard C; Duchaine C; Laprise C
J Infect Public Health; 2020 Nov; 13(11):1601-1610. PubMed ID: 32778421
[TBL] [Abstract][Full Text] [Related]
6. Cytokine storm induced by SARS-CoV-2.
Song P; Li W; Xie J; Hou Y; You C
Clin Chim Acta; 2020 Oct; 509():280-287. PubMed ID: 32531256
[TBL] [Abstract][Full Text] [Related]
7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
8. Severe Acute Respiratory Syndrome Coronavirus-2 Induces Cytokine Storm and Inflammation During Coronavirus Disease 19: Perspectives and Possible Therapeutic Approaches.
Mannino F; Bitto A; Irrera N
Front Pharmacol; 2020; 11():592169. PubMed ID: 33633566
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
10. Molecular Insights into COVID-19 Pathophysiology, Immune Pathogenesis, Detection, and Treatment.
Rezaei Z; Mobasheri L; Sadri F
DNA Cell Biol; 2021 Jul; 40(7):858-868. PubMed ID: 33989051
[TBL] [Abstract][Full Text] [Related]
11. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
Schijns V; Lavelle EC
Eur J Immunol; 2020 Jul; 50(7):932-938. PubMed ID: 32438473
[TBL] [Abstract][Full Text] [Related]
12. Aging in COVID-19: Vulnerability, immunity and intervention.
Chen Y; Klein SL; Garibaldi BT; Li H; Wu C; Osevala NM; Li T; Margolick JB; Pawelec G; Leng SX
Ageing Res Rev; 2021 Jan; 65():101205. PubMed ID: 33137510
[TBL] [Abstract][Full Text] [Related]
13. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
14. Insights into Novel Coronavirus Disease 2019 (COVID-19): Current Understanding, Research, and Therapeutic Updates.
Sushma DS; Jaiswal V; Kumar A; Asha S; Pal T
Recent Pat Biotechnol; 2022; 16(1):35-63. PubMed ID: 34353275
[TBL] [Abstract][Full Text] [Related]
15. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
Wang J; Jiang M; Chen X; Montaner LJ
J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
[TBL] [Abstract][Full Text] [Related]
16. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19.
Rohilla S
Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381
[TBL] [Abstract][Full Text] [Related]
17. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.
Lai CC; Shih TP; Ko WC; Tang HJ; Hsueh PR
Int J Antimicrob Agents; 2020 Mar; 55(3):105924. PubMed ID: 32081636
[TBL] [Abstract][Full Text] [Related]
18. Pathological diagnosis of Coronavirus-related nephropathy: insight from postmortem studies.
Sanguedolce F; Zanelli M; Froio E; Bisagni A; Zizzo M; Ascani S; Stallone G; Netti S; Ranieri E; Falagario U; Carrieri G; Cormio L
Crit Rev Clin Lab Sci; 2021 Dec; 58(8):563-575. PubMed ID: 34236278
[TBL] [Abstract][Full Text] [Related]
19. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
Noor R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
